ABVC BioPharma (ABVC)
(Delayed Data from NSDQ)
$0.78 USD
-0.01 (-1.52%)
Updated Jun 7, 2024 03:59 PM ET
After-Market: $0.78 0.00 (0.39%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ABVC 0.78 -0.01(-1.52%)
Will ABVC be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for ABVC based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for ABVC
ABVC Stock Earnings: ABVC BioPharma Reported Results for Q1 2024
Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection
PHG, IBRX and MESO are among premarket gainers
BACK, ZPTA and ABVC are among premarket gainers
Why Tesla Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket